Litcius/Paper detail

EML4‑ALK fusion gene in non‑small cell lung cancer (Review)

Yu Lei, Lei Yan, Xiang Shi, Jingjing Wang

2022Oncology Letters81 citationsDOIOpen Access PDF

Abstract

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate that is a threat to human health. With the development of molecular targeted research, breakthroughs have been made on the molecular mechanism of lung cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is one of the most important pathogenic driver genes of NSCLC discovered thus far. Four generations of targeted drugs for EML4-ALK have been developed, with patients benefiting significantly from these drugs. Therefore, EML4-ALK has become a research hotspot in NSCLC. The aim of the present study is to introduce the current research progress of EML4-ALK and its association with NSCLC.

Topics & Concepts

Anaplastic lymphoma kinaseLung cancerOncogeneMolecular medicineCancer researchFusion geneTargeted therapyCancerMedicineCell cycleOncologyBiologyGeneBioinformaticsInternal medicineGeneticsMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer-related Molecular Pathways